Heart disease deaths quadruple among young women — and most never saw it coming

American College of Cardiology — ACC.26 (Annual Scientific Session)

The numbers are hard to look away from: between 1999 and 2023, the rate at which American women aged 25 to 44 died from heart disease tied to high blood pressure more than quadrupled. It went from 1.1 per 100,000 deaths to 4.8. Over that quarter century, more than 29,000 young women died from a condition that, in most cases, can be detected with a simple cuff around the arm.

That finding, drawn from an analysis of U.S. death certificate data, is set to be presented at the American College of Cardiology's Annual Scientific Session (ACC.26) in New Orleans on March 29. The study's lead author, Alexandra Millhuff, DO, a resident physician at the University of New Mexico, put the implications bluntly: the medical system is underestimating cardiovascular risk in young women, diagnosing them too late, and missing chances to intervene early.

A blind spot in cardiology

High blood pressure affects nearly one in two American adults. It's sometimes called the "silent killer" because it damages the heart and blood vessels without producing obvious symptoms until the harm is already advanced. A person can walk around with dangerously elevated blood pressure for years, feeling perfectly fine, while the excess force against arterial walls slowly remodels the heart — thickening its walls, stiffening its chambers, and gradually eroding its ability to pump efficiently. Left unmanaged, chronic hypertension weakens the heart muscle and can lead to heart failure, coronary artery disease, heart attacks, and strokes.

But here's the problem: the bulk of research on hypertensive heart disease has focused on men and postmenopausal women. Younger women have largely been treated as low-risk, a population where aggressive cardiovascular screening seemed unnecessary. When a woman in her thirties visits her doctor, the conversation is far more likely to center on reproductive health, mental health, or routine bloodwork than on what her blood pressure numbers mean for her long-term cardiac outlook. This study suggests that assumption is costing lives.

The research team analyzed death certificates from women who died between ages 25 and 44 across the entire 1999-to-2023 period. The trajectory was unmistakable. What began as a relatively uncommon cause of death in this age group climbed steadily over two decades, reaching a rate more than four times higher by the end of the study window. To put it in raw terms: in 1999, hypertensive heart disease accounted for roughly one out of every 91,000 deaths in young women. By 2023, it was roughly one in every 21,000.

Race, region, and the unequal burden

The national average tells only part of the story. When the researchers broke the data down by race and geography, the disparities were stark.

Non-Hispanic Black women bore the heaviest toll by a wide margin, with a hypertension-related mortality rate of 8.6 per 100,000 — nearly four times the rate of 2.3 per 100,000 among non-Hispanic White women. That gap reflects longstanding inequities in healthcare access, treatment patterns, and the social determinants that drive chronic disease.

Geography mattered, too. Women in the South had the highest regional mortality rate at 3.8 per 100,000, followed by the Midwest at 2.8, the Northeast at 2.2, and the West at 1.9. One variable that did not appear to make a difference: whether women lived in urban or rural areas. The rates were comparable across both settings.

Why young women fall through the cracks

Several forces converge to make hypertension particularly dangerous for younger women. The first is clinical inertia — a well-documented phenomenon in which physicians are slow to intensify treatment even when clinical indicators call for it. Multiple studies have shown that women are prescribed blood pressure-lowering medications at lower rates than men, even when their readings warrant treatment. The reasons are tangled: some clinicians may perceive younger women as inherently protected by estrogen, while others may attribute elevated readings to white-coat anxiety or stress rather than treating them as a clinical warning. Heart disease awareness campaigns have historically centered on older populations, and the cultural image of a heart attack patient remains, stubbornly, a middle-aged man clutching his chest.

The second is biological. Women face cardiovascular risks tied to hormonal and physiological shifts during pregnancy and the perimenopausal transition. Gestational hypertension and preeclampsia, for instance, are well-established predictors of later heart disease — but the follow-through after delivery is often inadequate. The research team emphasized the importance of controlling blood pressure and managing risk factors so that women enter menopause and pregnancy in the best possible cardiovascular health.

"We need to be screening patients of this demographic for hypertension more aggressively, and that includes mitigating risk factors and possibly using antihypertensive medications," Millhuff said. "Even though hypertension is more prevalent in older populations, it's something that we need to be vigilant about in younger populations, as well."

The 130/80 threshold

Current ACC/AHA guidelines define high blood pressure as a reading at or above 130/80 mm Hg and stress the importance of early treatment to keep numbers below that mark. The first-line approach involves lifestyle modifications: quitting smoking, adopting a heart-healthy diet, and increasing physical activity. When those measures are not enough, blood pressure-lowering medications enter the picture.

The challenge is getting young women to that conversation in the first place. Most women in their twenties, thirties, and early forties do not regularly see a cardiologist. Their primary points of contact with the healthcare system are primary care providers and OB-GYNs — clinicians who may not prioritize cardiovascular screening in a patient population perceived as low-risk.

The researchers argue that this needs to change. Primary care and women's health providers are uniquely positioned to catch hypertension early in this group, and patients themselves can push the conversation forward by asking about their cardiovascular risk during routine visits. A blood pressure check takes less than a minute. The question is whether anyone thinks to prioritize it.

What the data cannot say

This study has meaningful limitations. It relies on death certificate data, which depends on how causes of death are coded — and coding practices can vary by state, over time, and by the clinician filling out the form. A rise in reported deaths could partly reflect improved recognition and documentation of hypertensive heart disease rather than a purely biological increase in the condition itself.

The study also cannot establish why rates are climbing. Possible contributors include rising rates of obesity and metabolic syndrome among younger adults, increased stress levels, declining physical activity, and worsening access to preventive care in some communities. Disentangling those factors would require different study designs.

Still, the signal is strong enough to warrant action. Even if coding improvements account for some of the increase, a fourfold rise over 24 years — with more than 29,000 deaths — points to a real and growing problem.

Where the gaps are widest

The racial disparity in the data is perhaps the most urgent finding. A mortality rate nearly four times higher among Black women than White women is not a statistical curiosity. It reflects a cascade of systemic failures: unequal access to routine care, lower rates of medication prescribing, higher prevalence of comorbid conditions, and the cumulative physiological toll of structural racism — what researchers increasingly refer to as weathering.

Addressing that gap will require more than awareness campaigns. It demands targeted screening programs, culturally competent care, and policy interventions that address the upstream drivers of cardiovascular disease in communities where the burden is heaviest. The data in this study do not explain the disparity — they simply make it impossible to ignore.

For Millhuff and her colleagues, the takeaway is practical rather than abstract. Young women are dying from a treatable condition at increasing rates, and the tools to reverse that trend already exist. Blood pressure monitoring is cheap and widely available. Antihypertensive medications are well-studied and effective. Lifestyle interventions — dietary changes, exercise, smoking cessation — are proven to reduce cardiovascular risk. What's missing is not technology or pharmacology. It's attention.

"Rising mortality for young women with hypertensive heart disease reflects an underestimation of cardiovascular risk, delayed diagnosis and missed opportunities for early intervention," Millhuff said. "This study underscores the urgent need for specific prevention strategies."

The study, titled "Rising Hypertensive Heart Disease Mortality in Young Women: 25-Year Trends and Disparities," will be presented on Sunday, March 29, at 9:30 a.m. CT during ACC.26 in New Orleans.